Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 8/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | BCL6 | P41182 | 1/20 | 0.38 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6892972 | 0.92 | PIN1 (0.49) | PIN1MAPK1CDK2KMT2AGSK3A | |
| SCHEMBL1804937 | 0.92 | PIN1 (0.56) | PIN1CDK2KMT2AGSK3AGSK3B | |
| SCHEMBL382894 | 0.89 | KMT2A (0.57) | PIN1MAPK1CDK2KMT2AGSK3A | |
| SCHEMBL27413443 | 0.89 | KMT2A (0.54) | PIN1MAPK1CDK2KMT2AGSK3A | |
| SCHEMBL23452638 | 0.88 | PIN1 (0.52) | PIN1CDK2KMT2AGSK3AGSK3B | |
| SCHEMBL8301782 | 0.88 | KMT2A (0.59) | PIN1MAPK1CDK2KMT2AGSK3A | |
| SCHEMBL29175759 | 0.88 | KMT2A (0.59) | PIN1MAPK1CDK2KMT2AGSK3A | |
| SCHEMBL14589028 | 0.85 | GSK3A (0.57) | PIN1CDK2KMT2AGSK3AGSK3B | |
| SCHEMBL1265078 | 0.85 | GSK3A (0.57) | PIN1CDK2KMT2AGSK3AGSK3B | |
| SCHEMBL1265079 | 0.85 | GSK3A (0.57) | PIN1CDK2KMT2AGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215108-B2 | Development of potential antidotes for arsenicals | SOUTHERN RESEARCH INSTITUTE (US) | 2025-02-04 | — | — | US | disclosed |
| CN-118027034-A | Purine derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023133354-A2 | DEVELOPMENT OF POTENTIAL ANTIDOTES FOR ARSENICALS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230219958-A1 | Development of Potential Antidotes for Arsenicals | THE UAB RESEARCH FOUNDATION | 2023-07-13 | — | — | US | disclosed |
| US-20230219958-A1 | Development of Potential Antidotes for Arsenicals | THE UAB RESEARCH FOUNDATION | 2023-07-13 | — | — | US | disclosed |
| CN-114249753-A | Triazolopyridine kinase inhibitors | 山东轩竹医药科技有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-9725450-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| EP-2493895-B1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | VECTURA LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| US-20160039822-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187479-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2112151-A2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1838710-B1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7521446-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2009-04-21 | — | — | US | disclosed |
| EP-2010186-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC | 2008-01-24 | — | — | US | disclosed |
| WO-2007127382-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1838710-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070060598-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | PHARMACOPEIA, LLC | 2006-12-21 | — | — | US | disclosed |
| WO-2006076595-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | PIN1 749/4885MAPK1 16/4885CDK2 275/4885 |
| US-12215108-B2 | Development of potential antidotes for arsenicals | RIPK1, RIPK3, RIPK4 | PIN1 3857/4885MAPK1 789/4885CDK2 885/4885 |
| US-20230219958-A1 | Development of Potential Antidotes for Arsenicals | RIPK1, RIPK3, RIPK4 | PIN1 3857/4885MAPK1 789/4885CDK2 885/4885 |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | TPMT, MGMT, SMAD3 | PIN1 1087/4885MAPK1 4/4885CDK2 306/4885 |
| US-20160039822-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | PIN1 1056/4885MAPK1 18/4885CDK2 311/4885 |
| US-20070060598-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | PIN1 1056/4885MAPK1 18/4885CDK2 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.